{"product_id":"p21-with-adamantane-10mg-vial","title":"P21 with adamantane 10mg vial","description":"\u003cp data-start=\"106\" data-end=\"480\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"106\" data-end=\"480\"\u003e\u003cstrong data-start=\"106\" data-end=\"129\"\u003eP21 with adamantane\u003c\/strong\u003e most commonly refers to \u003cstrong data-start=\"154\" data-end=\"176\"\u003ePeptide 021 (P021)\u003c\/strong\u003e—a \u003cstrong data-start=\"179\" data-end=\"224\"\u003esmall, CNS-directed, neurotrophic peptide\u003c\/strong\u003eengineered from a \u003cstrong data-start=\"243\" data-end=\"306\"\u003eshort active fragment of ciliary neurotrophic factor (CNTF)\u003c\/strong\u003e and \u003cstrong data-start=\"311\" data-end=\"367\"\u003echemically modified with an adamantane-based residue\u003c\/strong\u003e to increase lipophilicity, metabolic stability, and \u003cstrong data-start=\"420\" data-end=\"441\"\u003ebrain penetration\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"482\" data-end=\"753\"\u003eIn the original medicinal-chemistry \/ behavioral neuroscience line of work, \u003cstrong data-start=\"558\" data-end=\"565\"\u003eP21\u003c\/strong\u003e is described as an \u003cstrong data-start=\"585\" data-end=\"634\"\u003eadamantane-incorporating peptidergic compound\u003c\/strong\u003e that improved learning and memory and promoted hippocampal neurogenesis in mice. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"755\" data-end=\"1119\"\u003e\u003cstrong data-start=\"755\" data-end=\"783\"\u003eImportant naming caveat:\u003c\/strong\u003e “P21” is also used in biology to mean \u003cstrong data-start=\"822\" data-end=\"838\"\u003ep21 (CDKN1A)\u003c\/strong\u003e, a cell-cycle protein—completely unrelated to the CNTF-derived nootropic peptide. When you say “P21 with adamantine,” the CNTF-derived \u003cstrong data-start=\"974\" data-end=\"982\"\u003eP021\u003c\/strong\u003einterpretation is the one that matches the published “adamantane neurotrophic peptide” literature. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1121\" data-end=\"1124\"\u003e\n\u003ch3 data-start=\"1126\" data-end=\"1162\"\u003e2) Chemical design and rationale\u003c\/h3\u003e\n\u003ch4 data-start=\"1164\" data-end=\"1191\"\u003e2.1 Structural concept\u003c\/h4\u003e\n\u003cp data-start=\"1192\" data-end=\"1387\"\u003eThe design principle is: \u003cstrong data-start=\"1217\" data-end=\"1265\"\u003eretain a minimal CNTF-derived “active” motif\u003c\/strong\u003e but add a \u003cstrong data-start=\"1276\" data-end=\"1323\"\u003ehighly lipophilic adamantane building block\u003c\/strong\u003e (or adamantane-containing amino acid\/terminal substitution) to:\u003c\/p\u003e\n\u003cul data-start=\"1388\" data-end=\"1552\"\u003e\n\u003cli data-start=\"1388\" data-end=\"1429\"\u003e\n\u003cp data-start=\"1390\" data-end=\"1429\"\u003eincrease \u003cstrong data-start=\"1399\" data-end=\"1428\"\u003eresistance to proteolysis\u003c\/strong\u003e,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1430\" data-end=\"1465\"\u003e\n\u003cp data-start=\"1432\" data-end=\"1465\"\u003eimprove \u003cstrong data-start=\"1440\" data-end=\"1460\"\u003epharmacokinetics\u003c\/strong\u003e, and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1466\" data-end=\"1552\"\u003e\n\u003cp data-start=\"1468\" data-end=\"1552\"\u003eenhance \u003cstrong data-start=\"1476\" data-end=\"1513\"\u003eblood–brain barrier (BBB) passage\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-start=\"1554\" data-end=\"1578\"\u003e2.2 Why adamantane?\u003c\/h4\u003e\n\u003cp data-start=\"1579\" data-end=\"1913\"\u003eAdamantane is a rigid hydrophobic scaffold frequently used in CNS medicinal chemistry to improve membrane partitioning and stability. In this peptide program, the \u003cstrong data-start=\"1742\" data-end=\"1770\"\u003eadamantane incorporation\u003c\/strong\u003e is explicitly framed as a \u003cstrong data-start=\"1797\" data-end=\"1837\"\u003ebrain-delivery enabling modification\u003c\/strong\u003e for a very small peptide therapeutic. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1915\" data-end=\"1918\"\u003e\n\u003ch3 data-start=\"1920\" data-end=\"1956\"\u003e3) Molecular mechanism of action\u003c\/h3\u003e\n\u003ch4 data-start=\"1958\" data-end=\"2034\"\u003e3.1 Target pathway: CNTF\/LIF-like signaling (IL-6 family cytokine axis)\u003c\/h4\u003e\n\u003cp data-start=\"2035\" data-end=\"2553\"\u003eCNTF belongs to the \u003cstrong data-start=\"2055\" data-end=\"2079\"\u003eIL-6 cytokine family\u003c\/strong\u003e and signals via receptor complexes that converge on \u003cstrong data-start=\"2132\" data-end=\"2144\"\u003eJAK\/STAT\u003c\/strong\u003e pathways (notably \u003cstrong data-start=\"2163\" data-end=\"2172\"\u003eSTAT3\u003c\/strong\u003e). One mechanistic analysis of this peptide program describes P21 as acting relative to its parent motif by \u003cstrong data-start=\"2280\" data-end=\"2343\"\u003epartially inhibiting LIF activity through the STAT3 pathway\u003c\/strong\u003e in a cellular model—consistent with the idea that these small CNTF-derived peptides can modulate cytokine-linked signaling rather than acting as classic receptor agonists. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch4 data-start=\"2555\" data-end=\"2620\"\u003e3.2 Downstream neurotrophic biology (disease-relevant nodes)\u003c\/h4\u003e\n\u003cp data-start=\"2621\" data-end=\"2742\"\u003eAcross summaries and preclinical discussions, P021 is repeatedly connected to neurodegeneration-relevant nodes including:\u003c\/p\u003e\n\u003cul data-start=\"2743\" data-end=\"3020\"\u003e\n\u003cli data-start=\"2743\" data-end=\"2875\"\u003e\n\u003cp data-start=\"2745\" data-end=\"2875\"\u003e\u003cstrong data-start=\"2745\" data-end=\"2768\"\u003eBDNF-linked effects\u003c\/strong\u003e and downstream reduction of \u003cstrong data-start=\"2797\" data-end=\"2816\"\u003eGSK-3β activity\u003c\/strong\u003e, a major tau kinase (→ \u003cstrong data-start=\"2840\" data-end=\"2873\"\u003etau phosphorylation decreases\u003c\/strong\u003e),\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2876\" data-end=\"2938\"\u003e\n\u003cp data-start=\"2878\" data-end=\"2938\"\u003echanges consistent with \u003cstrong data-start=\"2902\" data-end=\"2933\"\u003esynaptic plasticity support\u003c\/strong\u003e, and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2939\" data-end=\"3020\"\u003e\n\u003cp data-start=\"2941\" data-end=\"3020\"\u003eneurogenic effects in hippocampal niches. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"3022\" data-end=\"3342\"\u003e\n\u003cp data-start=\"3024\" data-end=\"3342\"\u003eInterpretive note: Some of these pathway claims are synthesized from multiple preclinical reports and reviews; the field’s most consistent “direct” signal is \u003cstrong data-start=\"3182\" data-end=\"3230\"\u003eneurogenesis + cognitive performance in mice\u003c\/strong\u003e plus mechanistic work implicating cytokine\/STAT and tau-related pathways. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"3344\" data-end=\"3347\"\u003e\n\u003ch3 data-start=\"3349\" data-end=\"3425\"\u003e4) Pharmacokinetics and CNS exposure (what can be stated scientifically)\u003c\/h3\u003e\n\u003cp data-start=\"3426\" data-end=\"3578\"\u003eBecause P021 is \u003cstrong data-start=\"3442\" data-end=\"3486\"\u003enot an approved drug with a public label\u003c\/strong\u003e, PK details are largely derived from the design rationale and preclinical characterization:\u003c\/p\u003e\n\u003cul data-start=\"3580\" data-end=\"4162\"\u003e\n\u003cli data-start=\"3580\" data-end=\"3746\"\u003e\n\u003cp data-start=\"3582\" data-end=\"3746\"\u003e\u003cstrong data-start=\"3582\" data-end=\"3602\"\u003eBBB penetration:\u003c\/strong\u003e adamantane substitution is specifically described as facilitating BBB transport (lipophilicity-driven). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3747\" data-end=\"3940\"\u003e\n\u003cp data-start=\"3749\" data-end=\"3940\"\u003e\u003cstrong data-start=\"3749\" data-end=\"3763\"\u003eStability:\u003c\/strong\u003e adamantane incorporation is used to improve resistance to enzymatic breakdown (common goal in peptide optimization for systemic dosing). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3941\" data-end=\"4162\"\u003e\n\u003cp data-start=\"3943\" data-end=\"4162\"\u003e\u003cstrong data-start=\"3943\" data-end=\"3980\"\u003eRoute flexibility in animal work:\u003c\/strong\u003e published work includes \u003cstrong data-start=\"4005\" data-end=\"4034\"\u003eperipheral administration\u003c\/strong\u003e in mice with CNS effects, implying sufficient exposure to impact hippocampal biology. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4164\" data-end=\"4167\"\u003e\n\u003ch3 data-start=\"4169\" data-end=\"4214\"\u003e5) Preclinical and translational evidence\u003c\/h3\u003e\n\u003ch4 data-start=\"4216\" data-end=\"4272\"\u003e5.1 Cognition and neurogenesis in normal adult mice\u003c\/h4\u003e\n\u003cp data-start=\"4273\" data-end=\"4338\"\u003eA key preclinical report describes P21 administration leading to:\u003c\/p\u003e\n\u003cul data-start=\"4339\" data-end=\"4594\"\u003e\n\u003cli data-start=\"4339\" data-end=\"4452\"\u003e\n\u003cp data-start=\"4341\" data-end=\"4452\"\u003eimproved learning and memory (including \u003cstrong data-start=\"4381\" data-end=\"4403\"\u003eobject recognition\u003c\/strong\u003e and \u003cstrong data-start=\"4408\" data-end=\"4436\"\u003espatial reference memory\u003c\/strong\u003e paradigms), and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4453\" data-end=\"4594\"\u003e\n\u003cp data-start=\"4455\" data-end=\"4594\"\u003eincreased neurogenesis and maturation of newborn neurons in the \u003cstrong data-start=\"4519\" data-end=\"4553\"\u003edentate gyrus\/subgranular zone\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"4596\" data-end=\"4708\"\u003eThis is one of the more concrete, behavior + histology linked datasets supporting “nootropic\/neurogenic” claims.\u003c\/p\u003e\n\u003ch4 data-start=\"4710\" data-end=\"4788\"\u003e5.2 Disease-model positioning (Alzheimer’s and related neurodegeneration)\u003c\/h4\u003e\n\u003cp data-start=\"4789\" data-end=\"4913\"\u003eA peptide society monograph-style overview describes P21\/P021 as promising in preclinical AD-oriented contexts, emphasizing:\u003c\/p\u003e\n\u003cul data-start=\"4914\" data-end=\"5176\"\u003e\n\u003cli data-start=\"4914\" data-end=\"4984\"\u003e\n\u003cp data-start=\"4916\" data-end=\"4984\"\u003ereduction of abnormal tau phosphorylation (via BDNF\/GSK-3β framing),\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4985\" data-end=\"5066\"\u003e\n\u003cp data-start=\"4987\" data-end=\"5066\"\u003ereduction in amyloid-associated pathology signals (in preclinical reports), and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5067\" data-end=\"5176\"\u003e\n\u003cp data-start=\"5069\" data-end=\"5176\"\u003ea general neuroprotective profile relative to larger neurotrophins. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"5178\" data-end=\"5263\"\u003e\u003cem data-start=\"5178\" data-end=\"5263\"\u003e(This is still preclinical positioning; it does not substitute for human efficacy.)\u003c\/em\u003e\u003c\/p\u003e\n\u003ch4 data-start=\"5265\" data-end=\"5356\"\u003e5.3 More recent translational use: neurodevelopmental disease model (CDKL5 deficiency)\u003c\/h4\u003e\n\u003cp data-start=\"5357\" data-end=\"5695\"\u003eA 2024 open-access paper reports chronic oral \u003cstrong data-start=\"5403\" data-end=\"5411\"\u003eP021\u003c\/strong\u003e treatment in \u003cstrong data-start=\"5425\" data-end=\"5442\"\u003eCdkl5−\/Y mice\u003c\/strong\u003e, evaluating behavioral and related outcomes after extended dosing. This is relevant because it shows continued scientific interest beyond AD, using modern translational endpoints in a distinct CNS disorder model. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"5697\" data-end=\"5700\"\u003e\n\u003ch3 data-start=\"5702\" data-end=\"5752\"\u003e6) Safety, tolerability, and key uncertainties\u003c\/h3\u003e\n\u003ch4 data-start=\"5754\" data-end=\"5776\"\u003e6.1 What is known\u003c\/h4\u003e\n\u003cul data-start=\"5777\" data-end=\"6083\"\u003e\n\u003cli data-start=\"5777\" data-end=\"5943\"\u003e\n\u003cp data-start=\"5779\" data-end=\"5943\"\u003eThe peptide is repeatedly described as designed to avoid limitations of full-length neurotrophins (size, delivery), but \u003cstrong data-start=\"5899\" data-end=\"5942\"\u003ethat does not establish clinical safety\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5944\" data-end=\"6083\"\u003e\n\u003cp data-start=\"5946\" data-end=\"6083\"\u003ePublished work is predominantly \u003cstrong data-start=\"5978\" data-end=\"6002\"\u003eanimal + mechanistic\u003c\/strong\u003e; there is no widely cited, definitive human safety dataset in the sources above.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-start=\"6085\" data-end=\"6154\"\u003e6.2 What remains uncertain (high priority in any serious review)\u003c\/h4\u003e\n\u003cul data-start=\"6155\" data-end=\"6657\"\u003e\n\u003cli data-start=\"6155\" data-end=\"6248\"\u003e\n\u003cp data-start=\"6157\" data-end=\"6248\"\u003e\u003cstrong data-start=\"6157\" data-end=\"6190\"\u003eHuman safety and tolerability\u003c\/strong\u003e (dose-dependent adverse effects, chronic exposure risks).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6249\" data-end=\"6403\"\u003e\n\u003cp data-start=\"6251\" data-end=\"6403\"\u003e\u003cstrong data-start=\"6251\" data-end=\"6269\"\u003eImmunogenicity\u003c\/strong\u003e risk is generally lower for very small peptides than large proteins, but not zero—especially depending on formulation and impurities.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6404\" data-end=\"6657\"\u003e\n\u003cp data-start=\"6406\" data-end=\"6657\"\u003e\u003cstrong data-start=\"6406\" data-end=\"6437\"\u003eCytokine-pathway modulation\u003c\/strong\u003e (STAT3-related signaling) could, in principle, have wide-ranging effects depending on exposure and tissue context; this is one reason controlled clinical development is essential. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6659\" data-end=\"6662\"\u003e\n\u003ch3 data-start=\"6664\" data-end=\"6713\"\u003e7) Regulatory and clinical-development status\u003c\/h3\u003e\n\u003cul data-start=\"6714\" data-end=\"6982\"\u003e\n\u003cli data-start=\"6714\" data-end=\"6827\"\u003e\n\u003cp data-start=\"6716\" data-end=\"6827\"\u003e\u003cstrong data-start=\"6716\" data-end=\"6735\"\u003eInvestigational\u003c\/strong\u003e: P021\/P21 (adamantane-modified CNTF fragment) is \u003cstrong data-start=\"6785\" data-end=\"6809\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e as a therapeutic.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6828\" data-end=\"6982\"\u003e\n\u003cp data-start=\"6830\" data-end=\"6982\"\u003eCurrent evidence base is \u003cstrong data-start=\"6855\" data-end=\"6870\"\u003epreclinical\u003c\/strong\u003e, with ongoing academic\/translational exploration (e.g., mouse studies). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6984\" data-end=\"6987\"\u003e\n\u003ch3 data-start=\"6989\" data-end=\"7065\"\u003e8) How P21\/P021 fits within the broader “neurotrophic peptide” landscape\u003c\/h3\u003e\n\u003ch4 data-start=\"7067\" data-end=\"7100\"\u003e8.1 What makes it attractive\u003c\/h4\u003e\n\u003cul data-start=\"7101\" data-end=\"7331\"\u003e\n\u003cli data-start=\"7101\" data-end=\"7235\"\u003e\n\u003cp data-start=\"7103\" data-end=\"7235\"\u003e\u003cstrong data-start=\"7103\" data-end=\"7144\"\u003eSmall size + CNS delivery engineering\u003c\/strong\u003e (adamantane) tackles the classic neurotrophin problem: “great biology, poor druggability.”\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7236\" data-end=\"7331\"\u003e\n\u003cp data-start=\"7238\" data-end=\"7331\"\u003eTargets \u003cstrong data-start=\"7246\" data-end=\"7267\"\u003erepair\/plasticity\u003c\/strong\u003e mechanisms rather than single-symptom neurotransmitter effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-start=\"7333\" data-end=\"7375\"\u003e8.2 What typically blocks translation\u003c\/h4\u003e\n\u003cul data-start=\"7376\" data-end=\"7688\"\u003e\n\u003cli data-start=\"7376\" data-end=\"7554\"\u003e\n\u003cp data-start=\"7378\" data-end=\"7554\"\u003eMany compounds improve \u003cstrong data-start=\"7401\" data-end=\"7420\"\u003emouse cognition\u003c\/strong\u003e but fail in humans because of endpoint sensitivity, heterogeneity of disease biology, and insufficient target engagement measurement.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7555\" data-end=\"7688\"\u003e\n\u003cp data-start=\"7557\" data-end=\"7688\"\u003eFor neurogenic strategies, functional benefit often depends on \u003cstrong data-start=\"7620\" data-end=\"7687\"\u003etiming, circuit context, and concurrent rehabilitation\/training\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7690\" data-end=\"7693\"\u003e\n\u003ch3 data-start=\"7695\" data-end=\"7766\"\u003e9) Future directions (what would make the science “clinical-grade”)\u003c\/h3\u003e\n\u003cp data-start=\"7767\" data-end=\"7855\"\u003eIf this were being advanced as a serious therapeutic, the critical experiments would be:\u003c\/p\u003e\n\u003col data-start=\"7857\" data-end=\"8464\"\u003e\n\u003cli data-start=\"7857\" data-end=\"8067\"\u003e\n\u003cp data-start=\"7860\" data-end=\"8067\"\u003e\u003cstrong data-start=\"7860\" data-end=\"7884\"\u003eHuman PK\/PD bridging\u003c\/strong\u003e: confirm CNS exposure and measurable target engagement biomarkers (STAT3 pathway modulation, BDNF\/tau-related signatures where appropriate). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8068\" data-end=\"8217\"\u003e\n\u003cp data-start=\"8071\" data-end=\"8217\"\u003e\u003cstrong data-start=\"8071\" data-end=\"8102\"\u003eRobust functional endpoints\u003c\/strong\u003e: beyond memory tasks—include attention\/executive function batteries, digital biomarkers, and imaging correlates.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8218\" data-end=\"8368\"\u003e\n\u003cp data-start=\"8221\" data-end=\"8368\"\u003e\u003cstrong data-start=\"8221\" data-end=\"8242\"\u003eDisease selection\u003c\/strong\u003e: pick indications with clear mechanistic alignment (tauopathies, synaptic dysfunction disorders) and measurable biomarkers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8369\" data-end=\"8464\"\u003e\n\u003cp data-start=\"8372\" data-end=\"8464\"\u003e\u003cstrong data-start=\"8372\" data-end=\"8392\"\u003eLong-term safety\u003c\/strong\u003e: given neurotrophic pathway modulation, chronic safety is not optional.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-start=\"8466\" data-end=\"8469\"\u003e\n\u003ch2 data-start=\"8471\" data-end=\"8513\"\u003eSelected references (most load-bearing)\u003c\/h2\u003e\n\u003cul data-start=\"8514\" data-end=\"9098\"\u003e\n\u003cli data-start=\"8514\" data-end=\"8654\"\u003e\n\u003cp data-start=\"8516\" data-end=\"8654\"\u003e\u003cstrong data-start=\"8516\" data-end=\"8593\"\u003eAdamantane neurotrophic peptide program; cognition + neurogenesis in mice\u003c\/strong\u003e (Li et al., 2010): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8655\" data-end=\"8762\"\u003e\n\u003cp data-start=\"8657\" data-end=\"8762\"\u003e\u003cstrong data-start=\"8657\" data-end=\"8719\"\u003ePatent describing P21\/P22 and adamantane-containing design\u003c\/strong\u003e: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8763\" data-end=\"8894\"\u003e\n\u003cp data-start=\"8765\" data-end=\"8894\"\u003e\u003cstrong data-start=\"8765\" data-end=\"8851\"\u003ePeptide 021 (P021) description including adamantane substitution for BBB transport\u003c\/strong\u003e: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8895\" data-end=\"8991\"\u003e\n\u003cp data-start=\"8897\" data-end=\"8991\"\u003e\u003cstrong data-start=\"8897\" data-end=\"8935\"\u003eSTAT3\/LIF pathway mechanistic note\u003c\/strong\u003e (cell-based): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8992\" data-end=\"9098\"\u003e\n\u003cp data-start=\"8994\" data-end=\"9098\"\u003e\u003cstrong data-start=\"8994\" data-end=\"9055\"\u003eModern translational mouse study using P021 (CDKL5 model)\u003c\/strong\u003e: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684842959186,"sku":null,"price":70.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/P21_10mg.png?v=1770834807","url":"https:\/\/sciencepeptideslab.com\/products\/p21-with-adamantane-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}